Aromasin (exemestane) is now officially approved for POSTmenopausal women with early stage breast cancer
Aromasin (exemestane) is now officially approved for POSTmenopausal women with early stage breast cancer, who've received 2 to 3 years of tamoxifen.
Aromasin and tamoxifen work differently. Tamoxifen blocks estrogen receptors...and Aromasin blocks estrogen synthesis.
About 30% of women taking tamoxifen complain of side effects such as hot flashes, vaginal discharge, and vaginal bleeding.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote